1. J.A. Sipos, M.H. Shah, Thyroid cancer: emerging role for targeted therapies. Ther. Adv. Med. Oncol. 2, 3–16 (2010). doi: 10.1177/1758834009352667
2. G. Vitale, M. Caraglia, A. Ciccarelli, G. Lupoli, A. Abbruzzese, P. Tagliaferri, G. Lupoli, Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91, 1797–1808 (2001). doi: 10.1002/1097-0142(20010501)91:9
3. G.I. Manfredi, A. Dicitore, G. Gaudenzi, M. Caraglia, L. Persani, G. Vitale, PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine (2014). doi: 10.1007/s12020-014-0380-1
4. G. Vitale, G. Lupoli, R. Guarrasi, A. Colao, A. Dicitore, G. Gaudenzi, G. Misso, M. Castellano, R. Addeo, G. Facchini et al., Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. J. Clin. Endocrinol. Metab. 98, 1567–1574 (2013). doi: 10.1210/jc.2013-1443
5. A. Faggiano, V. Ramundo, A. Dicitore, S. Castiglioni, M.O. Borghi, R. Severino, P. Ferolla, L. Crinò, A. Abbruzzese, P. Sperlongano et al., Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J. Clin. Endocrinol. Metab. 16, 1563–1572 (2012). doi: 10.1111/j.1582-4934.2011.01438.x